Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 11, 2011 - Issue 2
Submit an article Journal homepage
153
Views
41
CrossRef citations to date
0
Altmetric
Research Report

Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the ‘5E’ study

Rafael Arroyo Neurology Service, Hospital Clínico San Carlos, C/ Martin Lago s/n 28040 Madrid, Spain. [email protected]
,
Carlos Vila Global Medical Affairs, Almirall, Ronda General Mitre 151, 08021 Barcelona, Spain
&
Steve Clissold Content Ed Net, Avenida de Burgos 9, Oficina 4, Madrid 28036, Spain
Pages 205-213 | Published online: 09 Jan 2014

References

  • Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult. Scler.10, 589–595 (2004).
  • Haselkorn JK, Balsdon RC, Fry WD, Herndon RM, Johnson B, Little JW; Multiple Sclerosis Council for Clinical Practice Guidelines. Overview of spasticity management in multiple sclerosis. Evidence-based management strategies for spasticity treatment in multiple sclerosis. J. Spinal Cord Med.28(2), 167–199 (2005).
  • Bohannon RW, Smith MB. Inter-rater reliability of a modified Ashworth scale of muscle spasticity. Phys. Ther.67, 206–207 (1987).
  • Farrar JT, Troxel AB, Stott CG, Duncombe P. The validity, reliability, and clinical importance of changes in spasticity severity measured on a 0–10 Numerical Rating Scale. J. Neurol.254(Suppl. 3), 21 (2007).
  • Farrar JT, Troxel AB, Stott C, Duncombe P, Jensen MP. Validity, reliability, and clinical importance of change in a 0–10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin. Ther.30(5), 974–985 (2008).
  • Penn RD, Savoy SM, Corcos D et al. Intrathecal baclofen for severe spinal spasticity. N. Engl. J. Med.320(23), 1517–1521 (1989).
  • Hobart JC, Riazi A, Thompson AJ et al. Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). Brain129, 224–234 (2006).
  • Bavikatte G, Gaber T. Approach to spasticity in general practice. Br. J. Med. Pract.2, 29–34 (2009).
  • Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Sys. Rev.4, CD001332 (2003).
  • Zwibel HL. Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv. Ther.26(12), 1043–1057 (2009).
  • Sharac J, McCrone P, Sabes-Figuera R. Pharmacoeconomic considerations in the treatment of multiple sclerosis. Drugs70(13), 1677–1691 (2010).
  • Kobelt G, Berg J, Lindgren P, Fredrikson S, Jönsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J. Neurol. Neurosurg. Psychiatry77, 918–926 (2006).
  • Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology33, 1444–1451 (1983).
  • Anwar K, Barnes MP. A pilot study of a comparison between a patient scored numeric rating scale and clinician scored measures of spasticity in multiple sclerosis. Neurorehabilitation24, 333–340 (2009).
  • Ansari NN, Naghdi S, Arab TK, Jalaie S. The interrater and intrarater reliability of the modified Ashworth scale in the assessment of muscle spasticity: limb and muscle group effect. Neurorehabilitation23, 231–237 (2008).
  • Hauser SL, Dawson DM, Lehrich JR et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high dose intravenous cyclophosphamide, plasma exchange, and ACTH. N. Engl. J. Med.308, 173–180 (1983).
  • Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, Calne DB. Treatment of spasticity with botulinum toxin: a double-blind study. Ann. Neurol.28, 512–515 (1990).
  • Anon. Aids to the investigation of peripheral nerve injury. War Memorandum Number 45. HMSO, London, UK (1976)
  • Buhse M. Assessment of caregiver burden in families of persons with multiple sclerosis. J. Neurosci. Nurs.40, 25–31 (2008).
  • Stevenson VL. Rehabilitation in practice: spasticity management. Clin. Rehabil.24, 293–304 (2010).
  • Fleuren JF, Voerman GE, Erren-Wolters CV et al. Stop using the Ashworth Scale for the assessment of spasticity. J. Neurol. Neurosurg. Psychiatry81, 46–52 (2010).
  • Casado V, Romero L, Gubieras L et al. An approach to estimating the intangible costs of multiple sclerosis according to disability in Catalonia, Spain. Mult. Scler.13(6), 800–804 (2007).
  • Pryce G, Baker D. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br. J. Pharmacol.150, 19–25 (2007).
  • House H, Bateman C, Wade DT. Long-term Sativex (THC:CBD) use in multiple sclerosis: benefits to daily life and functional activities. Mult. Scler.13, S267 (2007).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.